DRONEDARONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C31H44N2O5S
Molecular Weight	556.756
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C2=C(CCCC)OC3=CC=C(NS(C)(=O)=O)C=C23

InChI

InChIKey=ZQTNQVWKHCQYLQ-UHFFFAOYSA-N

InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C31H44N2O5S
Molecular Weight	556.756
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/ppa/dronedarone.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6 | http://www.rxlist.com/multaq-drug.htm

Dronedarone is an antiarrhythmic that is FDA approved for the treatment of atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). Dronedarone is multichannel blocker. Common adverse reactions include abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia and raised serum creatinine. Dronedarone has potentially important pharmacodynamics interactions: Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor; Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability; Beta-blockers: May provoke excessive bradycardia, Initiate with low dose and increase after ECG verification of tolerability.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Inward rectifier potassium channel 2 5 Target ID: CHEMBL1914276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25182566	Blocker 537
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 14 Target ID: CHEMBL1250417 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21279331	Blocker 537	1.0 µM [IC50]
Cytochrome P450 3A4 127 Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17389667 \| http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Substrate 661

Conditions

Condition	Modality	Targets	Highest Phase	Product
Atrial fibrillation 131 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Primary		Approved 8429	MULTAQ Approved Use MULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) Launch Date 2009
Atrial flutter 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Primary		Approved 8429	MULTAQ Approved Use MULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) Launch Date 2009

C_max

Value	Dose	Co-administered	Analyte	Population
96.2 ng/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/full/10.1046/j.1472-8206.2003.00216.x	1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: METOPROLOL	METOPROLOL	DRONEDARONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1386 ng × h/mL EXPERIMENT https://onlinelibrary.wiley.com/doi/full/10.1046/j.1472-8206.2003.00216.x	1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: METOPROLOL	METOPROLOL	DRONEDARONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
12 h EXPERIMENT https://onlinelibrary.wiley.com/doi/full/10.1046/j.1472-8206.2003.00216.x	1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: METOPROLOL	METOPROLOL	DRONEDARONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	unhealthy, 20-97 years n = 3282 Health Status: unhealthy Condition: atrial fibrillation \| atrial flutter Age Group: 20-97 years Sex: M+F Population Size: 3282 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Disc. AE: Gastrointestinal disorders, QT interval prolonged... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (3.2%) QT interval prolonged (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
1600 mg 2 times / day multiple, oral Highest studied dose Dose: 1600 mg, 2 times / day Route: oral Route: multiple Dose: 1600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf https://pubmed.ncbi.nlm.nih.gov/17056831	healthy, 21-40 years Health Status: healthy Age Group: 21-40 years Sex: M Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf https://pubmed.ncbi.nlm.nih.gov/17056831	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf https://pubmed.ncbi.nlm.nih.gov/17056831
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103	unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation \| atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103	Disc. AE: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (6.7%) Nausea (3.9%) Abdominal pain upper (2%) Abdominal pain (1.9%) Vomiting (1.7%) Dyspepsia (1.3%) Nasopharyngitis (3.7%) Upper respiratory tract infection (2.9%) Dizziness (3.4%) Blood creatinine increased (2.5%) Hepatic enzyme increased (1.2%) Blood urea increased (0.4%) Bradycardia (2.6%) Palpitations (1.1%) Cardiac failure congestive (1.3%) Cardiac failure (0.8%) Fatigue (2.7%) Oedema peripheral (4.2%) Back pain (3.3%) Arthralgia (3.1%) Pain in extremity (2.1%) Cough (2.2%) Dyspnoea (2.3%) Vertigo (1.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103
400 mg 2 times / day steady, oral Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: NYHA Class IV heart failure \| NYHA Class II - III heart failure Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Other AEs: Heart failure... Other AEs: Heart failure (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103	unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation \| atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103	Disc. AE: Diarrhea, Vomiting... AEs leading to discontinuation/dose reduction: Diarrhea (7.6%) Vomiting (1.5%) Dyspepsia (3%) Abdominal pain (1.5%) Nasopharyngitis (4.5%) Electrocardiogram QT prolonged (1.5%) Blood creatinine increased (1.5%) Hepatic enzyme increased (4.5%) Blood urea increased (3%) Bradycardia (1.5%) Palpitations (6.1%) Cardiac failure congestive (4.5%) Cardiac failure (4.5%) Fatigue (4.5%) Cough (1.5%) Hypokalemia (3%) Vertigo (4.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103	unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation \| atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103	Disc. AE: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (29%) Nausea (8.1%) Vomiting (3.2%) Abdominal pain (3.2%) Influenza (3.2%) Upper respiratory tract infection (1.6%) Dizziness (4.8%) Electrocardiogram QT prolonged (3.2%) Hepatic enzyme increased (1.6%) Blood urea increased (3.2%) Bradycardia (6.5%) Palpitations (4.8%) Cardiac failure congestive (1.6%) Cardiac failure (1.6%) Fatigue (3.2%) Atrial tachycardia (4.8%) Cough (4.8%) Vertigo (3.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf Page: p. 103

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inducer 389 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C19 1478 CYP2E1 882 P-gp 1461 OAT1 599 OAT3 642 OCT1 512 OATP1B1 788 OATP1B3 706	CYP3A 191 CYP1A2 1054 P-gp 1537	CYP1A2 701 CYP2A6 79 CYP3A 129 CYP2C8 168 CYP2C19 293

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022425s029lbl.pdf#page=13 Page: 13.0	likely
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022425s029lbl.pdf#page=13 Page: 13.0	likely
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89,194	moderate [Ki 8.12 uM]	yes (co-administration study) Comment: dronedarone increased verapamil exposure by 1.4- fold, and nisoldipine exposure by 1.5- fold; dronedarone increased simvastatin, a sensitive CYP3A substrate, and simvastatin acid exposure by 4- fold and 2- fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89,194
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP2A6 739	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP2C8 965	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP3A 298	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	not significant
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	not significant
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	not significant
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022425s029lbl.pdf#page=13 Page: 13.0	not significant
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022425s029lbl.pdf#page=13 Page: 13.0	not significant
OCT1 543	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022425s029lbl.pdf#page=13 Page: 13.0	not significant
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	not significant	weak (co-administration study) Comment: dronedarone increased S-warfarin exposure by 1.2- fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0
P-gp 1650	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,90	strong [IC50 0.97 uM]	yes (co-administration study) Comment: IC50 value obtained using vincristine as substrate; increased S-warfarin exposure by 1.2- fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,90
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89,194	weak [Ki 4.37 uM]	yes (co-administration study) Comment: dronedarone increased metoprolol exposure by 1.6- and 2.3- fold, respectively; increased propranolol exposure by 1.3- fold; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89,194

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A 191	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89	major	yes (co-administration study) Comment: administration of ketoconazole resulted in a 17- to 25- fold increase in dronedarone exposure; administration with rifampicin decreased dronedarone exposure by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0	unlikely

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_Pharm_P1.pdf#page=59 Page: 59.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:50659	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50659
ChemicalBook	CB11117179	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB11117179
MolPort	MolPort-006-170-000	https://www.molport.com/shop/molecule-link/MolPort-006-170-000
ZINC	ZINC000049933061	http://zinc15.docking.org/substances/ZINC000049933061
eMolecules	30152747	https://www.emolecules.com/cgi-bin/more?vid=30152747

PubMed

Title	Date	PubMed
[Dronedarone establishes and maintains control of sinus rhythm].	2006 Aug 23	16972539
[Dronedarone--a new therapeutic option for controlling atrial rhythm and ventricular frequency].	2006 Aug 25	16921447
Do we need pharmacological therapy for atrial fibrillation in the ablation era?	2006 Dec	17340189
Comment on dronedarone.	2006 Dec	17096652
Dronedarone: a new antiarrhythmic agent.	2006 Feb	16541184
Dose-dependent effects of oral dronedarone on the circadian variation of RR and QT intervals in healthy subjects: implications for antiarrhythmic actions.	2006 Sep	17056831
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.	2006 Sep	17002263
Topics on the Na+/Ca2+ exchanger: pharmacological characterization of Na+/Ca2+ exchanger inhibitors.	2006 Sep	16990699
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.	2007 Apr	17389667
Effect of dronedarone on renal function in healthy subjects.	2007 Dec	17662087
Dronedarone in atrial fibrillation.	2007 Dec 6	18069129
Dronedarone in atrial fibrillation.	2007 Dec 6	18057346
Dronedarone: in quest of the ideal antiarrhythmic drug.	2007 Fall	18059201
Pharmacological inhibition of TRalpha1 receptor potentiates the thyroxine effect on body weight reduction in rats: potential therapeutic implications in controlling body weight.	2007 Jan	17199732
Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components.	2007 Jun	17535870
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?	2007 Nov	17967585
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.	2007 Oct 17	17943835
Maintaining sinus rhythm--making treatment better than the disease.	2007 Sep 6	17804851
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.	2007 Sep 6	17804843
[Efficacy of dronedarone in cardiac failure due to severe left ventricular systolic dysfunction. Results of the ANDROMEDA].	2008	19076098
Atrial fibrillation after cardiac surgery: where are we now?	2008	18982137
[Efficacy of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Results of the EURIDIS and ADONIS].	2008	18789030
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.	2008	18651412
[Amiodaron for treatment of perioperative cardiac arrythmia: a broad spectrum antiarrythmetic agent?].	2008 Dec	18704341
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.	2008 Jan	18031520
Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug.	2008 Jun	18827865
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.	2008 Jun	18515286
Pharmacotherapy for atrial arrhythmias: present and future.	2008 Jun	18456197
Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.	2008 Jun	18392809
Increased mortality after dronedarone therapy for severe heart failure.	2008 Jun 19	18565860
Update on atrial fibrillation: part II.	2008 Mar	18383050
Is dronedarone effective for the prevention of recurrent atrial fibrillation?	2008 Mar	18087298
Dronedarone: a new treatment for atrial fibrillation.	2008 Nov	18702618
Amiodarone as paradigm for developing new drugs for atrial fibrillation.	2008 Oct	18841075
New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.	2008 Oct	18523740
[Current pharmacological management of atrial fibrillation management by practice cardiologists - news from congress in Munich].	2008 Sep	19004121
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.	2008 Sep	18760136
Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452.	2008 Sep	18678526
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?	2008 Sep 22	18790110
Trial watch: novel antiarrhythmic agent shows promise in Phase III trial.	2009 Apr	19337265
Alternatives to amiodarone: search for the Holy Grail.	2009 Apr	19223364
A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.	2009 Apr	19174378
Dronedarone for atrial fibrillation--an odyssey.	2009 Apr 30	19403901
Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, beta-interferon study, BACH, and ATHENA.	2009 Feb	19168521
Effect of dronedarone on cardiovascular events in atrial fibrillation.	2009 Feb 12	19213680
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?	2009 Jan	19077816
Benzofuran derivatives and the thyroid.	2009 Jan	18727707
Major recent trials in cardiovascular diseases.	2009 Mar	19332959
New pharmacological options for patients with atrial fibrillation: the ATHENA trial.	2009 May	19406061
The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches.	2010 Mar	19096930

Patents

Sample Use Guides

In Vivo Use Guide

One tablet of 400 mg twice a day with morning and evening meals.

Route of Administration: Oral

In Vitro Use Guide

In isolated ventricular myocytes, dronedarone inhibited rapidly activating delayed-rectifier K+ current (I(Kr)) (median inhibitory concentration [IC50] /= 30 uM).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:18:50 GMT 2023` Edited by `admin` on `Fri Dec 15 16:18:50 GMT 2023`
Record UNII	JQZ1L091Y2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DRONEDARONE

Official Name

English

dronedarone [INN]

Common Name

English

METHANESULFONAMIDE, N-(2-BUTYL-3-(4-(3-(DIBUTYLAMINO)PROPOXY)BENZOYL)-5-BENZOFURANYL)-

Systematic Name

English

SR33589

Code

English

SR-33589

Code

English

DRONEDARONE [VANDF]

Common Name

English

N-(2-BUTYL-3-(4-(3-(DIBUTYLAMINO)PROPROXY)BENZOYL)BENZOFURAN-5-YL)METHANESULFONAMIDE

Common Name

English

DRONEDARONE [EMA EPAR]

Common Name

English

Dronedarone [WHO-DD]

Common Name

English

DRONEDARONE [MI]

Common Name

English

DRONEDARONE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC01BD07